Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sionna Therapeutics, Inc. - Common Stock
(NQ:
SION
)
36.73
+1.98 (+5.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
406,683
Open
34.81
Bid (Size)
14.61 (200)
Ask (Size)
58.41 (200)
Prev. Close
34.75
Today's Range
33.98 - 37.11
52wk Range
13.51 - 48.45
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
May 27, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-6.3%
-6.3%
1 Month
-6.4%
-6.4%
3 Month
+2.5%
+2.5%
6 Month
-14.4%
-14.4%
1 Year
+156.7%
+156.7%
More News
Read More
Sionna Therapeutics Reports First Quarter 2026 Financial Results
May 12, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch
↗
April 27, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
April 27, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
April 07, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
↗
March 30, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
↗
March 21, 2026
Via
The Motley Fool
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
↗
March 18, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
↗
March 15, 2026
Via
The Motley Fool
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 02, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
February 23, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares
↗
January 12, 2026
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million
↗
January 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
November 24, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
November 04, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 28, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 27, 2025
Via
Benzinga
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
October 24, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
October 21, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
October 01, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
September 08, 2025
From
Sionna Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Sionna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?
Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?
The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market
What is the current price of Sionna Therapeutics, Inc. - Common Stock?
The current price of Sionna Therapeutics, Inc. - Common Stock is 36.73
When was Sionna Therapeutics, Inc. - Common Stock last traded?
The last trade of Sionna Therapeutics, Inc. - Common Stock was at 06/17/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
